NewsBenzingaOS Therapies Completes Requalification Of Phase 2b Herlystic Drug Substance For Confirmatory Phase 3 Trial OS Therapies Completes Requalification Of Phase 2b Herlystic Drug Substance For Confirmatory Phase 3 Trial Benzinga 2026.11.05 13:14 (GMT+0) Open on Benzinga Other news TD Cowen Maintains Buy on Kiniksa Pharmaceuticals, Raises Price Target to $115 B. Riley Securities Maintains Buy on Almonty Indus, Lowers Price Target to $18 TD Cowen Maintains Hold on Elastic, Lowers Price Target to $85 B. Riley Securities Maintains Buy on AirJoule Technologies, Lowers Price Target to $6 UBS Maintains Buy on American Airlines Group, Raises Price Target to $17 If You Invested $1000 In State Street Technology Select Sector SPDR ETF Stock 15 Years Ago, You Would Have This Much Today
If You Invested $1000 In State Street Technology Select Sector SPDR ETF Stock 15 Years Ago, You Would Have This Much Today